Andrew Bodey

  • Webinar recorded on Thu 27th April, 2017
  • 1 hours 1 mins
  • 1 Comment

Feline Hyperthyroidism: Talking Points by Andrew Bodey. Drawing on his experience from having managed ~1,000 cases of feline hyperthyroidism using radio-iodine treatment, Andrew Bodey discusses:

  • challenges and vulnerabilities in making the diagnosis, reviewing diagnostic tests in detail
  • adverse effects of conventional medication
  • challenges of RIT
  • discusses the role of homeopathy in feline hyperthyroidism by discussing a placebo-controlled RCT published this month
  • case selection for RIT

Learning Objectives

  • Understand the limitations of laboratory data in diagnosing feline hyperthyroidism
  • An improved awareness of potential adverse effects of methimazole
  • An awareness of published claims of homeopathy in treating feline hyperthyroidism and the results of a prospective placebo-controlled randomised clinical trial using homeopathy
  • An improved awareness of appropriate case selection for radio-iodine treatment
  • An improved understanding of evidence-based medicine and its relevance to clinical practice.

Andrew Bodey qualified from Bristol in 1989, and spent 2 years in mixed practice in Staffordshire before moving to companion animals in the south east. In 1995 he moved to North Yorkshire, obtaining his CertVR in 2003. From this he further developed his interest in ionizing radiation, and solved his frustration at having to refer hyperthyroid cats either to Glasgow or Newmarket by establishing the first radio-iodine unit in the North of England, in 2008. In the process he reduced the minimum hospitalization period in the UK to 2 weeks. In September 2013 he founded the Hyperthyroid Cat Centre, near Wetherby, the largest radio-iodine facility in Europe, and further reduced the minimum hospitalization period to only 5 days.  He has published clinical research on hyperthyroidism in collaboration with the university of Cambridge and is actively involved in ongoing research projects.


Read More

Please consider one of the following membership levels to enable you to view this webinar...